Characteristics of interstitial lung disease and radiological features
| Delay of occurrence between pneumonitis and introduction of immunotherapy months | 2.3 (0.2–27.4) |
| 0–2 | 27 (42.2) |
| 2–4 | 17 (26.6) |
| 4–6 | 11 (17.2) |
| >6 | 9 (14.1) |
| CTCAE grade | |
| 1 | 10 (15.6) |
| 2 | 25 (39.1) |
| 3 | 17 (26.6) |
| 4 | 6 (9.4) |
| 5 | 6 (9.4) |
| BAL# | |
| Yes | 35 (55.6) |
| No | 28 (44.4) |
| Unknown | 1 |
| Lymphocytes¶ % | 33.5 (1.0–70.0) |
| ≤15 | 6 (20.0) |
| >15 | 24 (80.0) |
| Unknown | 5 |
| Evolution# | |
| Recovery | 18 (28.6) |
| Improvement | 25 (39.7) |
| Stable | 13 (20.6) |
| Worsening | 1 (1.6) |
| Fatal | 6 (9.5) |
| Unknown | 1 |
| Radiological features | |
| Lesions | |
| GGO | 52 (81.3) |
| Consolidations | 34 (53.1) |
| Intralobular lines | 14 (21.9) |
| Interlobular septal thickening | 10 (15.6) |
| Traction bronchectasis | 11 (17.2) |
| Extent (lobes) n | 3 (1–5) |
| Pattern | |
| Organising pneumonia | 15 (23.4) |
| Hypersensitivity pneumonia | 10 (15.6) |
| NSIP and organising pneumonia | 6 (9.4) |
| NSIP | 5 (7.8) |
| Bronchiolitis | 4 (6.3) |
| NSIP and bronchiolitis | 1 (1.6) |
| No classification | 23 (35.9) |
Data are presented as median (range) or n (%). n=64, unless otherwise stated. CTCAE: Common Toxicity Criteria for Adverse Events, version 4.0; BAL: bronchoalveolar lavage; GGO: ground-glass opacity; NSIP: nonspecific interstitial pneumonitis. #: n=63; ¶: n=30.